Liraglutide monthly Depot
Product Description
Nanexa AB
-
Country/Region:Sweden
-
On CPHI since:2024
-
Certificates:2
-
Employees:25 - 49
Company types
Primary activities
Categories
Specifications
Nanexa AB
-
Country/Region:Sweden
-
On CPHI since:2024
-
Certificates:2
-
Employees:25 - 49
Company types
Primary activities
Nanexa AB resources (1)
-
News Nanexa’s Phase I trial of NEX-22 in type 2- diabetes progresses with next dose group according to plan
Nanexa AB today announces that the company's Phase 1 study for type 2 diabetes continues dose escalation according to plan with their long-acting depot formulation of the GLP-1 analog liraglutide.